Close Menu

NEW YORK (GenomeWeb) – Molecular diagnostics firm Invitae has partnered with gene therapy developer Spark Therapeutics to launch a free genetic testing program for patients suspected of having inherited retinal disease (IRD).

In a separate deal, Invitae also partnered with X4 Pharmaceuticals to provide free genetic testing for WHIM syndrome and Severe Congenital Neutropenia (SCN), a group of rare inherited primary immunodeficiencies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.